Shares of Dermira Inc. (NASDAQ:DERM) traded down 3.6% during mid-day trading on Monday . The stock traded as low as $29.52 and last traded at $29.81, with a volume of 150,498 shares changing hands. The stock had previously closed at $30.91.

Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research report on Friday. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Dermira in a research report on Wednesday, June 22nd. Leerink Swann restated a “buy” rating and set a $47.00 target price (up from $46.00) on shares of Dermira in a research report on Thursday, June 2nd. Finally, Wedbush upped their target price on shares of Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.71.

The company has a 50-day moving average price of $30.06 and a 200 day moving average price of $26.70. The company’s market cap is $908.64 million.

Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.01. On average, equities research analysts anticipate that Dermira Inc. will post ($3.51) EPS for the current year.

In related news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $25.09, for a total transaction of $62,725.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Christopher M. Griffith sold 4,405 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $30.16, for a total transaction of $132,854.80. Following the transaction, the vice president now owns 48,043 shares in the company, valued at $1,448,976.88. The disclosure for this sale can be found here.

Other institutional investors have bought and sold shares of the company. Wells Fargo & Company MN raised its position in Dermira by 424.6% in the fourth quarter. Wells Fargo & Company MN now owns 41,036 shares of the biopharmaceutical company’s stock worth $1,420,000 after buying an additional 33,213 shares during the last quarter. Jennison Associates raised its position in Dermira by 98.7% in the third quarter. Jennison Associates now owns 1,013,343 shares of the biopharmaceutical company’s stock worth $23,651,000 after buying an additional 503,237 shares during the last quarter. Morgan Stanley raised its position in Dermira by 82.2% in the fourth quarter. Morgan Stanley now owns 42,767 shares of the biopharmaceutical company’s stock worth $1,480,000 after buying an additional 19,299 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Dermira by 8.3% in the fourth quarter. Jennison Associates LLC now owns 1,097,201 shares of the biopharmaceutical company’s stock worth $37,974,000 after buying an additional 83,858 shares during the last quarter.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.